What happened with SOPH today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
SOPHiA GENETICS SA helps hospitals and laboratories interpret genomic and other complex health data through its SOPHiA DDM Platform. Laboratories can generate sequencing data with their own equipment and upload it for analysis, or buy DNA enrichment kits bundled with the software. Customers generally keep custody of their samples and data. Platform access is free for clinical customers, who pay for each analysis; these customers supply most revenue, and oncology accounts for most clinical application revenue where the disease area is known.
Its smaller, still-developing biopharma business sells customized analysis and data insights for drug research and development. SOPHiA Trial Match, for example, alerts participating institutions when a genomic profile matches a trial sponsor’s eligibility criteria.
Revenue depends on customers continuing and expanding their analysis activity. One distributor supplies a significant share of sales, and the platform relies heavily on Microsoft Azure for computing and hosting. In the United States, the company sells its applications and products for research use only and cannot make clinical or diagnostic claims. It plans to seek authorization for diagnostic use, which requires FDA clearance or approval.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Tempus AI competes with SOPHiA GENETICS for healthcare-provider and biopharma spending on genomic analysis, insights combining different kinds of healthcare data, and matching patients to trials. Watch Tempus’s data-licensing and Trials business for competition facing SOPHiA’s biopharma services.
Caris Life Sciences, Inc. competes with SOPHiA GENETICS for clinical and biopharma customers buying cancer genomic profiling and insights that combine molecular and clinical data. Its tissue-based MI Profile and blood-based Caris Assure offerings are worth watching because oncology, including hereditary cancer, supplied about 73% of SOPHiA’s 2025 clinical revenue from applications with a known disease end market.
Guardant Health competes with SOPHiA GENETICS in cancer genomic profiling and tests that help select patients for a drug, selling tests to clinical customers and diagnostic-development services to biopharma companies. Its patent suits in the UK and at the Unified Patent Court directly challenge SOPHiA’s MSK-Access blood-based cancer test; watch the requests for injunctions and damages, which remain allegations rather than findings of infringement.
Myriad Genetics Inc competes with SOPHiA GENETICS in hereditary-cancer testing and diagnostics that help drug companies select patients, but the two are also developing a blood-based companion diagnostic for pharmaceutical customers. Watch Myriad’s planned adoption of SOPHiA DDM for clinical laboratory testing and its lead role in US regulatory submissions; SOPHiA is to pursue approvals outside the US.
Illumina sells sequencing instruments and recurring supplies to laboratories whose data SOPHiA GENETICS analyzes, so clinical sequencing use matters to both, even as they compete in analysis software. Watch Illumina’s clinical-laboratory consumables business alongside SOPHiA’s paid analysis volume, rather than treating instrument sales as a direct measure of SOPHiA revenue.
QIAGEN supplies consumables and equipment that SOPHiA GENETICS bundles with analysis for laboratory customers, while competing with SOPHiA’s Alamut software in interpreting genomic changes. Its consumables and workflow offerings are the relevant part to watch for SOPHiA’s bundled testing business, rather than QIAGEN’s sales as a whole.
Agilent Technologies collaborates on products that prepare DNA samples for sequencing, including enrichment kits used in SOPHiA GENETICS’ laboratory workflows, while also competing in genomic-analysis software. Those kits connect directly to SOPHiA’s bundled business: laboratory customers buy a DNA enrichment kit with each analysis, with kit revenue recognized on delivery and analysis revenue when results are delivered.
Fed Interest Rate Decision
SOPHiA GENETICS’ Fed interest-rate decision matters because it can influence the cost of interest on its Perceptive loans and of future borrowing as the company funds its platform and ongoing losses.
Expected4.0%Last release4.0%
If it comes in above expectations
If the Fed sets rates higher than expected, market borrowing costs may rise, increasing interest expense on any debt whose rate resets and making new funding more costly as the company supports its platform and operations.
If it comes in below expectations
If the Fed sets rates lower than expected, market borrowing costs may fall, easing interest expense on any debt whose rate resets and reducing the cost of future funding for the platform and operations.
Illumina Inc earningsILMN
Illumina's clinical-laboratory consumables business will show whether sequencing activity is rising or easing, a market signal for SOPHiA GENETICS' paid analysis volume.
Watch the direction of Illumina's clinical-laboratory consumables business alongside SOPHiA GENETICS' chargeable analysis volume. Stronger consumables activity would point to more sequencing work at laboratories and more samples that could need analysis; weaker activity would signal a softer backdrop for clinical sequencing. Illumina's instrument and consumables sales are not SOPHiA's revenue, so the conclusion is whether that activity is translating into paid analyses for SOPHiA.
Tempus AI, Inc. earningsTEM
Tempus AI's report will show how its data-licensing and trial-matching businesses are doing, a read on its competition with SOPHiA GENETICS for biopharma budgets.
Focus on Tempus AI's data-licensing and trial-matching businesses, and compare their direction with SOPHiA GENETICS' insights and trial-matching services for biopharma. Evidence of stronger demand and adoption in those Tempus businesses would mean tougher competition for biopharma budgets; weakness would suggest less pressure from this rival, but would not prove that SOPHiA's demand is rising. The conclusion is whether competition in these services is intensifying or easing for SOPHiA.
SOPHiA GENETICS SA earningsThis company
SOPHiA GENETICS charges many clinical customers per analysis, and this report will show whether greater platform use is bringing in revenue while protecting gross margin.
Read chargeable analysis volume and platform revenue alongside gross margin and cost of revenue. If volume and revenue grow while margin holds, greater use by existing customers or new customers is bringing in enough revenue to cover the cost of serving them. If volume slows or revenue fails to keep pace and margin falls, growth is not translating fully into revenue, or costs such as computing and storage are squeezing the profit on each sale. The conclusion is whether platform use is turning into healthier business.
Caris Life Sciences, Inc. earningsCAI
Caris Life Sciences' report will show the direction of cancer genomic profiling, a competitive signal for the largest part of SOPHiA GENETICS' clinical applications business.
Watch the direction of Caris's tissue- and blood-based cancer profiling, keeping in mind that oncology accounted for about 73% of SOPHiA GENETICS' 2025 clinical revenue from applications with a known disease end market. Stronger demand for these tests would signal an active oncology market, but also a rival pursuing the same clinical and biopharma customers; weakness would point to pressure in a market important to SOPHiA. The conclusion is that oncology activity is both a demand signal and a competition signal for SOPHiA.
Myriad Genetics Inc earningsMYGN
Myriad Genetics' report may show progress in adopting SOPHiA DDM and pursuing US submissions for a blood-based companion diagnostic, key steps in putting their partnership to work.
Look for updates on Myriad's planned use of SOPHiA DDM in clinical laboratory testing and its lead role in US regulatory submissions. Progress on both would show the partnership moving toward platform use in clinical testing and advancement of the blood-based companion diagnostic; limited progress or delays would leave that route to adoption and regulatory clearance uncertain. The conclusion is whether this specific partnership is moving from plan to execution.
Guardant Health, Inc. earningsGH
Guardant Health's report may update its patent suits over SOPHiA GENETICS' MSK-Access blood-based cancer test, which could affect the risk to sales in the UK and EU.
Look for Guardant's updates on the UK and Unified Patent Court cases, especially any movement on its requests for injunctions and damages. If the dispute narrows or no new sales restriction emerges, a legal obstacle to SOPHiA's MSK-Access commercialization in the UK and EU may ease; if the cases advance toward a risk of an injunction, sales or commercialization could still be disrupted. Guardant's claims are allegations, not findings of infringement. The conclusion is whether the litigation risk to this product's commercialization has changed.
Agilent Technologies Inc. earningsA
Agilent Technologies' report will show demand for DNA enrichment kits and related laboratory workflows, a signal for SOPHiA GENETICS' bundled testing business.
Watch Agilent's kit business tied to sequencing sample preparation alongside SOPHiA GENETICS' chargeable analysis volume in bundled workflows. Stronger kit demand may point to more laboratory use of these workflows. In SOPHiA's bundle model, kit revenue is generally recognized on delivery and analysis revenue when results are delivered. Weaker kit demand could signal pressure on that business. Agilent's sales are not SOPHiA's revenue, so the conclusion is whether laboratory activity is showing up in SOPHiA's own bundled business.
